Zytiga’s revenue trends
In 4Q17, Johnson & Johnson’s Zytiga generated revenues of $755.0 million, which reflected ~45.5% growth on a year-over-year (or YoY) basis. In 4Q17, in the US market and outside the US markets (international markets), Zytiga generated revenues of $402.0 million and $353.0 million, respectively, compared to $249.0 million and $270.0 million, which reflected ~61.4% and ~30.7% growth on a YoY basis.
In fiscal 2017, JNJ’s Zytiga reported revenues of $2.5 billion, which is ~11.0% growth on a YoY basis. In 2017, in the US markets and international markets, Zytiga reported revenues of $1.2 billion and $1.3 billion, respectively, compared to $1.1 billion and $1.2 billion in 2016, which reflected ~13.0% and ~10.0% YoY growth.
In February 2018, the FDA approved a new indication for Johnson & Johnson’s Zytiga. The FDA approved Zytiga and prednisone combination therapy for the treatment of individuals with metastatic high-risk castration-sensitive prostate cancer (or CSPC).
The FDA approval of Zytiga was based on the results of the pivotal Phase 3 LATITUDE trial. In the LATITUDE trial, Zytiga and prednisone combination therapy demonstrated a reduction in the risk of death by 38.0% compared to placebo.
In February 2018, Health Canada also approved Zytiga for the treatment of newly diagnosed metastatic prostate cancer. The FDA and Health Canada approval of the new indication for Zytiga is expected to boost the sales growth of the drug in 2018. Zytiga (abiraterone acetate) is presently approved for the treatment of individuals with metastatic castration-resistant prostate cancer and CSPC.
According to the Canadian Cancer Society, around 21,300 men are diagnosed with prostate cancer every year. According to American Cancer Society estimates, 164,690 new cases of prostate cancer and 29,430 deaths due to prostate cancer is anticipated in the US in 2018.